ArticleDiscover oncology2025
Gender influences prognosis of classical BCR::ABL1 negative myeloproliferative neoplasms: a retrospective cohort study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic value of gender in classical BCR::ABL1 negative myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) remains unclear.
methodsWe conducted a retrospective study utilizing the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the prognostication of gender in MPNs patients. The Kaplan-Meier and Cox proportional hazards regression analysis were performed to calculate the survival outcomes of male and female patients with MPNs.
resultsOf 50,510 patients diagnosed with MPNs from 2000 - 2021, 24,583 patients (48.7%) were male and 25,927 patients (51.3%) were female. The Kaplan-Meier survival analysis revealed decreased overall survival in male against female in entire MPNs (median survival: 132.0 versus 145.0 months; P < 0.001), which was also documented in ET (median survival: 131.0 versus 168.0 months, P < 0.001) and PMF (median survival: 43.0 versus 66.0 months, P < 0.001) but opposite results in PV (median survival: 162.0 versus 137.0 months, P < 0.001). In multivariate analysis adjusted with age, year of diagnosis, race, annual income and marital status, male gender independently predicted shortened overall survival compared with female in entire MPNs (HR 1.39, 95% CI 1.35-1.43; P < 0.001). Male gender predicted decreased overall survivalacross ET and PMF (HR 1.65, 95% CI 1.57-1.73 and HR 1.48, 95% CI 1.38-1.59 respectively; all P < 0.001) but alsoin PV (HR 1.14, 95% CI 1.09-1.19, P < 0.001). Propensity score matching analysis revealed that male patients suffered worse outcomes in entire MPNs, but heterogeneous effect of male gender on survival were seen across subgroups: no prognostic impact was detected in PV, whereas -decreased overall survival were consistently observed in ET and PMF. In entire MPNs, the dynamic risk of male gender against female for overall survival increased with year of diagnosis but decreased with age of diagnosis. From early years of diagnosis to later years, the hazard ratio of male gender on survival prognosis displayed an upward trend in PV and PMF, whereas a downward trend from 2000 to 2005 followed by an upward trend in later years was documented in ET. From younger to older aging, the adverse effect of male gender on survival prognosis remained nearly stable in PV but displayed a downward trend in ET, whereas it culminated around age 70 followed by a gradual decline in PMF.
conclusionsGender should be considered in prognosis stratification of ET and PMF, whereas the prognostic value of gender in PV remained elusive.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.